Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

N-acetylcysteine lacks universal inhibitory activity against influenza A viruses.

Garigliany MM, Desmecht DJ.

J Negat Results Biomed. 2011 May 9;10:5. doi: 10.1186/1477-5751-10-5.

2.

Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses.

Kumar N, Sharma NR, Ly H, Parslow TG, Liang Y.

Antimicrob Agents Chemother. 2011 Dec;55(12):5553-9. doi: 10.1128/AAC.00725-11. Epub 2011 Sep 19.

3.

N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus.

Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl J Jr.

Biochem Pharmacol. 2010 Feb 1;79(3):413-20. doi: 10.1016/j.bcp.2009.08.025. Epub 2009 Sep 2.

PMID:
19732754
4.

Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.

Haasbach E, Pauli EK, Spranger R, Mitzner D, Schubert U, Kircheis R, Planz O.

Antiviral Res. 2011 Sep;91(3):304-13. doi: 10.1016/j.antiviral.2011.07.006. Epub 2011 Jul 13.

PMID:
21777621
5.

Inhibition of influenza virus replication by plant-derived isoquercetin.

Kim Y, Narayanan S, Chang KO.

Antiviral Res. 2010 Nov;88(2):227-35. doi: 10.1016/j.antiviral.2010.08.016. Epub 2010 Sep 6.

PMID:
20826184
6.

In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.

Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL.

Antiviral Res. 2011 Nov;92(2):329-40. doi: 10.1016/j.antiviral.2011.09.001. Epub 2011 Sep 8.

7.

Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.

Yu J, Wang D, Jin J, Xu J, Li M, Wang H, Dou J, Zhou C.

Antiviral Res. 2016 Mar;127:68-78. doi: 10.1016/j.antiviral.2016.01.011. Epub 2016 Jan 21.

PMID:
26802558
8.

Germacrone inhibits early stages of influenza virus infection.

Liao Q, Qian Z, Liu R, An L, Chen X.

Antiviral Res. 2013 Dec;100(3):578-88. doi: 10.1016/j.antiviral.2013.09.021. Epub 2013 Oct 3.

PMID:
24095670
9.

In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.

Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2010 Jun;54(6):2517-24. doi: 10.1128/AAC.01739-09. Epub 2010 Mar 29.

10.
11.

[In vitro and in vivo anti-influenza virus activity of ribavirin injection].

Gao RM, Li XQ, He WY, Jiang JD, Li YH.

Yao Xue Xue Bao. 2010 Mar;45(3):403-7. Chinese.

PMID:
21351521
12.

Antiviral potential of exogenous human omega interferon to inhibit pandemic 2009 A (H1N1) influenza virus.

Xu C, Song X, Fu L, Dong D, Wu S, Li G, Yi S, Yu T, Yu R, Hou L, Chen W.

Viral Immunol. 2011 Oct;24(5):369-74. doi: 10.1089/vim.2011.0003.

PMID:
22004136
13.

Identification of small molecules that interfere with H1N1 influenza A viral replication.

Bottini A, De SK, Baaten BJ, Wu B, Barile E, Soonthornvacharin S, Stebbins JL, Bradley LM, Chanda SK, Pellecchia M.

ChemMedChem. 2012 Dec;7(12):2227-35. doi: 10.1002/cmdc.201200453. Epub 2012 Nov 8.

14.

Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus.

Hsieh CF, Lo CW, Liu CH, Lin S, Yen HR, Lin TY, Horng JT.

J Ethnopharmacol. 2012 Aug 30;143(1):57-67. doi: 10.1016/j.jep.2012.05.061. Epub 2012 Jun 16.

PMID:
22710290
15.

Efficacy of influenza vaccination and tamifluĀ® treatment--comparative studies with Eurasian Swine influenza viruses in pigs.

Duerrwald R, Schlegel M, Bauer K, Vissiennon T, Wutzler P, Schmidtke M.

PLoS One. 2013 Apr 22;8(4):e61597. doi: 10.1371/journal.pone.0061597. Print 2013.

16.

The effect of rosuvastatin in a murine model of influenza A infection.

Radigan KA, Urich D, Misharin AV, Chiarella SE, Soberanes S, Gonzalez A, Perlman H, Wunderink RG, Budinger GR, Mutlu GM.

PLoS One. 2012;7(4):e35788. doi: 10.1371/journal.pone.0035788. Epub 2012 Apr 20.

17.

Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.

Conti G, Magliani W, Conti S, Nencioni L, Sgarbanti R, Palamara AT, Polonelli L.

Antimicrob Agents Chemother. 2008 Dec;52(12):4331-7. doi: 10.1128/AAC.00506-08. Epub 2008 Sep 29.

18.

Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo.

Haasbach E, Droebner K, Vogel AB, Planz O.

J Interferon Cytokine Res. 2011 Jun;31(6):515-25. doi: 10.1089/jir.2010.0071. Epub 2011 Feb 16.

PMID:
21323570
19.

Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.

Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, Gramer MR, Swafford S, DeLiberto T, Govorkova EA, Webster RG.

J Virol. 2010 Oct;84(19):9800-9. doi: 10.1128/JVI.00296-10. Epub 2010 Jul 21.

20.

N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury.

Zhang RH, Li CH, Wang CL, Xu MJ, Xu T, Wei D, Liu BJ, Wang GH, Tian SF.

Int Immunopharmacol. 2014 Sep;22(1):1-8. doi: 10.1016/j.intimp.2014.06.013. Epub 2014 Jun 24.

PMID:
24968347

Supplemental Content

Support Center